The World Health Organisation (WHO) is working with national health authorities on the continent to bolster surveillance and laboratory diagnosis to detect cases and deter a silent spread of the monkeypox virus. By Tuesday, June 28, the continent had reported 1821 cases in 13 countries, of which 109 are laboratory-confirmed in nine countries. The number of confirmed cases in Africa accounts for 2% of the more than 4500 confirmed cases globally. However, there are a large number of suspected cases in the region, 81% of which are in the Democratic Republic of the Congo, underlining the need for increased diagnostic capacity. According to information from the WHO African Regional Office, all African countries have the Polymerase Chain Reaction (PCR) machines needed to test for monkeypox, thanks to reinforced laboratory capacity in the wake of Covid-19, many lack reagents and in some cases don’t have enough training in specimen collection, handling and testing. “WHO is working to secure 60,000 tests for Africa, with around 2,000 tests and reagents to be shipped to high-risk countries and 1000 to those facing lower risk,” reads a statement from WHO Africa on Thursday, June 30. Over the past month, five more African countries have received donations of reagents from partners, bringing to 12 the number of countries in the region with enhanced monkeypox diagnostic capacity. Another group of countries in West Africa will receive reagents after participating in a training. “The geographic spread of monkeypox to parts of Africa where cases have never been detected before is a worrying sign,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “It is critical that we support national efforts to boost surveillance and laboratory diagnosis, which are the cornerstones of disease control,” she said. Outside the six countries in Africa with a history of human transmission, monkeypox has also been reported in three countries which have not previously had any human cases. These include Ghana, Morocco and South Africa, which has confirmed the disease in two patients with no travel history, suggesting there is a high possibility of local transmission. To deepen analysis of monkeypox transmission patterns, WHO is supporting countries to capitalise on the improved genomic sequencing capacity built during the Covid-19 pandemic. Currently, seven countries can sequence the monkeypox virus. The WHO has reports from South Africa and Nigeria which show the two countries have sequenced 300 samples since January 2022 – these include samples from other countries. This is more than double all the samples sequenced in previous years. Most samples sequenced were from the West African clade. The sequencing done so far shows that there is no recent linkage between what is circulating in Europe and Africa. Many years of research have led to the development of new and safer (second- and third-generation) vaccines for smallpox, some of which may be useful for monkeypox and one of which (MVA-BN) has been approved for prevention of monkeypox. However, supplies are limited. “What happened in the early days of the COVID-19 vaccine rollout when Africa watched on the side-lines as other countries snapped up limited supplies must not be allowed to recur. There are some signs that this is already happening,” said Dr Moeti. “The current global spotlight on monkeypox should be a catalyst to beat this disease once and for all in Africa. For this, we know vaccines are a critical tool,” she added. WHO is working closely with Member States and partners to define what type of coordination mechanism could be put in place to ensure fair access to vaccines. There are many regulatory, legal, operational, technical, and other issues to clarify before an allocation mechanism is fully operational. With limited vaccines and antivirals, WHO does not recommend mass vaccination for monkeypox but rather targeted vaccination for people who have been exposed or at high risk including health workers, laboratory personnel and outbreak team responders.
